Isoniazid-Resistant Tuberculosis - A Series of Clinical Cases

Author:

Butnaru Teodora12,Mihălţan Florin Dumitru12,Bivolaru Sorin3,Constantin Ancuţa12

Affiliation:

1. University of Medicine and Pharmacy “Carol Davila” , Department of Pneumology II, Division of Cardiothoracic Pathology IV , , Bucharest , Romania

2. Institute of Pneumology “Marius Nasta” , Medical Department III Pneumology , Bucharest , Romania

3. University of Medicine and Pharmacy “Dunărea de Jos” , , Galaţi , Romania

Abstract

Abstract The emergence of M. tuberculosis strains resistant to Isoniazid (INH) and Rifampicin (RIF), the two most potent drugs of first-line anti-TB treatment is termed multidrug drug-resistant TB (MDR-TB). Multidrug-resistant tuberculosis has been a severe medical and epidemic problem worldwide. We present a series of clinical cases consisting of two patients diagnosed with isoniazid-resistant tuberculosis. Histopathological examination supports the diagnosis of tuberculous granulomas. The pathology molecular examination revealed the presence of Isoniazid-resistant Mycobacterium tuberculosis 1, 2 via the following mutation c.947G>A; p. Gly316Asp. Isoniazid-resistance is associated with mutations in the furA-katG and fabG1-inhA operons and in the ahpC gene. 64% of the isoniazid-resistance phenotypes were associated with the kat G 315 mutation worldwide. The second most common mutation is inhA-15, reported in 19% of the Isoniazid-resistant isolates. The significant association between the two mutations, inhA c-15 and kat G 315 respectively, and the high-level resistance is of interest in the interpretation of current and future molecular diagnostic testing, as an early prediction of the level of Isoniazid-resistance is essential to decide the benefit of high-dose Isoniazid use.

Publisher

Walter de Gruyter GmbH

Reference27 articles.

1. Global Tuberculosis Report 2022. World Health Organization, 2022.

2. The End TB Strategy. World Health Organization; 2014. http://www.who.int/tb/strategy/end-tb/en/. Accessed March 14, 2019.

3. National Guideline for the Management of Drug-resistant Tuberculosis Cases 2020. Romanian Society of Pneumology 2020. Official Gazette no. 917 bis 2020.10.8

4. Paul Ioan Stoicescu et al. Management of Multidrug Resistant Tuberculosis Cases. Ministry of Health, "Marius Nasta" Institute of Pneumology, National Tuberculosis Control Program; 2005

5. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization; 2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3